Biomarker-based screening for ovarian and lung cancer using immune system signals
Official title: High-throughput immunoproteomics for cancer biomarker discovery
Funded at Arizona State University-Tempe Campus · NIH-11412502 · Data updated 2026-11-12
A research program is developing blood-based immune biomarkers to help screen for ovarian and lung cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arizona State University-Tempe Campus NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $924,710 |
| NIH project number | 5U2CCA271903-05 |
| Project ID | NIH-11412502 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals at risk for or being screened for ovarian or lung cancer who consent to participate in biomarker studies.
✕Less likely to help
People without cancer risk factors or those whose biomarkers do not indicate cancer may not gain direct benefit.
What this research studies
This project uses advanced immunoproteomics to identify autoantibodies and anti-microbial antibodies in blood samples from people at risk for ovarian or lung cancer. Researchers will examine how cancer-related proteins, their modifications, and immune responses create circulating biomarkers that could improve early detection. The approach combines system-wide immune profiling with prior validation work to create multiplex panels that enhance predictive value. The goal is a clinically useful blood test that complements existing screening methods. The team has prior experience and is building on validated models to move toward a reliable screening tool.
Why it matters
Potential benefit: If successful, patients could benefit from earlier cancer detection through a simple blood test.
How similar studies have gone: Previous autoantibody biomarker work has progressed to blinded phase 2 validation and led to a CLIA-certified test, supporting further development.
Where this research is happening
-
Arizona State University-Tempe Campus
Scottsdale, United States Active
Researchers
- Principal investigator: Labaer, Joshua — Arizona State University-Tempe Campus
- Study coordinator: Labaer, Joshua
Related research
Other NIH-funded projects on the same topics.
-
Understanding how herpesviruses move and exit cells (focus on HSV-1 and PRV)
Scientists are studying how herpesviruses travel inside nerve cells and exit at the right spots, which could lead to better prevention and treatment of infections in people and animals.
-
Whole Protein Arrays to Find Antibodies Linked to Islet Autoimmunity in a Big Birth Cohort
This NIH grant aims to map antibodies against many microbes in children from the TEDDY study to understand what infections might be linked to the development of type 1 diabetes.
-
Climate heat and Alzheimer's risk in older adults
Heat exposure may influence brain health and dementia risk in older adults living in the United States.
-
Certified Cancer Registry Extraction with Proof-Certified Trust
A new AI-powered system helps cancer registries extract standardized data from medical records more accurately and with formal proofs to ensure trust.
-
Demystifying E. coli ecosystems with synthetic microbial communities
A project builds controlled, synthetic E. coli communities to uncover how different interactions shape colony behavior and health-related outcomes.
-
Aflatoxin exposure and child growth in Guatemala
A study in rural Guatemala will track how exposure to aflatoxin relates to growth and gut health in young children.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.